Search research articles
Contact Us
Filters
Showing results (101-110 of 134) with videos related to
Page
of 14
Sort By:
JAMA Dermatology
|
August 31, 2023
Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma
Neel M Helvind, Marie Brinch-Møller Weitemeyer, Annette H Chakera, et al.
Annals of Surgical Oncology
|
February 8, 2023
Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients
Neel Maria Helvind, Marie Brinch-Møller Weitemeyer, Annette Hougaard Chakera, et al.
Journal of the National Cancer Institute
|
June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
Marna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
Stine K Christensen, Mette L Winther, Ida J Laursen, et al.
Lancet (London, England)
|
April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 29, 2006
The Danish national guidelines for treatment of oral squamous cell carcinoma
Anders Bilde, Christian von Buchwald, Jørgen Johansen, et al.
Frontiers in Endocrinology
|
July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 134) with videos related to
Sort By:
Page
of 14
JAMA Dermatology
|
August 31, 2023
Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma
Neel M Helvind, Marie Brinch-Møller Weitemeyer, Annette H Chakera, et al.
Annals of Surgical Oncology
|
February 8, 2023
Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients
Neel Maria Helvind, Marie Brinch-Møller Weitemeyer, Annette Hougaard Chakera, et al.
Journal of the National Cancer Institute
|
June 11, 2009
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon
Marna G Bouwhuis, Stefan Suciu, Sandra Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
Stine K Christensen, Mette L Winther, Ida J Laursen, et al.
Lancet (London, England)
|
April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 29, 2006
The Danish national guidelines for treatment of oral squamous cell carcinoma
Anders Bilde, Christian von Buchwald, Jørgen Johansen, et al.
Frontiers in Endocrinology
|
July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Page
of 14